drugset / Trial / NCT04311411

A Study of Tirzepatide in Overweight and Very Overweight Participants

NCT04311411

Phase 1 Completed 114 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight. The study will also use imaging to learn more about how tirzepatide affects specific parts of the brain. The effect of tirzepatide on appetite will also be studied. The study will last up to about four months and will include up to 14 visits to the study center.

Timeline

Start
2020-08-24
Primary completion
2022-12-16
Completion
2022-12-16

Drugs

EvaluationDrugModalityDoseRoute
Comparator Liraglutide Peptide 3 mg Subcutaneous
Subject Tirzepatide Peptide 10 mg Subcutaneous

Indications